Piper Sandler Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has initiated coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with an Overweight rating and a price target of $33.
September 28, 2023 | 9:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's Overweight rating and price target of $33 for Cerevel Therapeutics could potentially boost the stock's performance in the short term.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Piper Sandler's Overweight rating indicates that they expect Cerevel Therapeutics' stock to outperform the average market return. Additionally, the price target of $33 suggests a potential upside for the stock, which could attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100